• Regulatory NewsRegulatory News

    Teva’s Cephalon Reaches $125m Settlement With 48 States Due to Generic Delays

    Teva Pharmaceutical’s Cephalon and state attorneys general on Thursday announced a $125 million, 48-state settlement after an investigation into the company’s delaying of generic versions of its top product. Cephalon, which denies any wrongdoing and was acquired by Teva in 2011, was accused of delaying generic versions of its sleep disorder drug Provigil (modafinil). The settlement with every state and Washington, DC (but not including California and Louisiana) follows...